Hepion Pharmaceuticals, Inc.
HEPA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HEPA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases, currently pursuing a strategic alternatives strategy and advancing a Phase 3 clinical trial for its lead candidate.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials · 1 catalyst for Hepion Pharmaceuticals, Inc..
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases, currently pursuing a strategic alternatives strategy and advancing a Phase 3 clinical trial for its lead candidate.
- Hepion has no products approved for commercial sale in the U.S. but has three CE-marked products eligible for sale in the EU through a licensing agreement [sec_mda · as of 2026-03-12].
- The company reported cash and equivalents of $1.6M, net income of -$1.2M, and shareholders' equity of -$1.9M as of 2026-06-30 [sec].
- Hepion raised gross proceeds of $3.1 million in a July 2026 private placement, closing on August 3, 2026 [sec_mda · as of 2026-08-13].
- The company has a Phase 3 top-line data readout scheduled for October 5, 2027 [catalyst].
- Hepion continues to expend substantial resources on its strategic alternatives strategy and development of acquired assets [sec_mda · as of 2026-08-13].
What works
- Hepion has three CE-marked products that are eligible for sale in the EU and certain other markets, providing a potential revenue stream [sec_mda · as of 2026-03-12].
- The company successfully raised $3.1 million in a July 2026 private placement, indicating some investor support [sec_mda · as of 2026-08-13].
- Hepion is advancing a Phase 3 clinical trial with a top-line data readout expected in October 2027, which could be a significant value inflection point [catalyst].
What to weigh
- Hepion has no products approved for commercial sale in the United States and has generated limited revenue to date [sec_mda · as of 2026-03-12].
- The company reported negative shareholders' equity of -$1.9M as of 2026-06-30, indicating a weak balance sheet [sec].
- Hepion's cash position of $1.6M as of 2026-06-30 is low relative to its ongoing development and operational costs, raising financing risk [sec].
- The company has a history of net losses, with a net loss of $1.2M in the most recent quarter [sec].
From the filings
Quoted directly from source documents.
Hepion has no U.S.-approved products but has CE-marked products for the EU.
“We have no products approved for commercial sale in the United States. However, with the assets related to the New Day licensing agreement, there are three products that have CE marks and are eligible to be sold in the European Union”
SEC MD&A · March 12, 2026
Catalyst timeline
- 2027-10-05 · Phase3_Topline — Top-line data from a Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating efficacy.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash of $1.6M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- Negative shareholders' equity — Shareholders' equity of -$1.9M as of 2026-06-30 indicates a weak financial position [sec].
- No U.S. approved products — No products approved for commercial sale in the U.S., with limited revenue from EU sales [sec_mda · as of 2026-03-12].
- Clinical trial risk — Phase 3 top-line data expected in 2027; failure could significantly impact the company's prospects [catalyst].
What to watch
- Phase 3 top-line data readout scheduled for October 5, 2027 [catalyst].
- Ability to secure additional financing given low cash and negative equity [sec].
- Revenue generation from CE-marked products in the EU [sec_mda · as of 2026-03-12].
- Progress on strategic alternatives strategy and potential asset acquisitions [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Hepion Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Hepion Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.7 months
D/E 0.51 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~401d
11 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Hepion Pharmaceuticals, Inc.?
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for liver diseases, currently pursuing a strategic alternatives strategy and advancing a Phase 3 clinical trial for its lead candidate.
What is Hepion Pharmaceuticals, Inc.'s next catalyst?
Hepion Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy " — expected October 5, 2027.
Who is the CEO of Hepion Pharmaceuticals, Inc.?
Mr. Gary S. Stetz C.P.A. is the chief executive officer of Hepion Pharmaceuticals, Inc. (HEPA).
Where is Hepion Pharmaceuticals, Inc. headquartered?
Hepion Pharmaceuticals, Inc. (HEPA) is headquartered in Morristown, NJ, United States.
What therapeutic areas does Hepion Pharmaceuticals, Inc. focus on?
Hepion Pharmaceuticals, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.